Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Axsome Therapeutics, Inc.

< Previous 1 2 Next >
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.